Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.40 |
| ▸ | PAK1 | Q13153 | 7/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | PAK4 | O96013 | 1/20 | 0.40 |
| ▸ | SGK1 | O00141 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | CAMKK1 | Q8N5S9 | 1/20 | 0.40 |
| ▸ | SGK3 | Q96BR1 | 1/20 | 0.40 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.40 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL296763 | 0.99 | CYP2C9 (0.42) | CYP2C9AXLIGF1RPAK1ACLY | |
| SCHEMBL298714 | 0.87 | PAK1 (0.43) | AXLIGF1RPAK1PAK4AURKA | |
| SCHEMBL296762 | 0.86 | PAK1 (0.42) | AXLIGF1RPAK1PAK4AURKA | |
| SCHEMBL3714332 | 0.83 | JAK3 (0.40) | CYP2C9AXLPAK1PAK4SGK1 | |
| SCHEMBL7872687 | 0.74 | AAK1 (0.50) | AXLPAK1PAK4AURKASGK2 | |
| SCHEMBL298879 | 0.72 | CYP2C9 (0.49) | CYP2C9PAK1RIPK1 | |
| SCHEMBL298205 | 0.72 | CAMKK2 (0.49) | CYP2C9PAK1CAMKK2RIPK1 | |
| SCHEMBL298320 | 0.72 | CYP2C9 (0.48) | CYP2C9PAK1RIPK1 | |
| SCHEMBL298745 | 0.71 | CAMKK2 (0.52) | CYP2C9AXLPAK1PAK4AURKA | |
| SCHEMBL298881 | 0.71 | CAMKK2 (0.48) | CYP2C9PAK1CAMKK2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CYP2C9 2176/4885AXL 470/4885IGF1R 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.